Adaptation and validation of a German version of the Multimorbidity Treatment Burden Questionnaire

Schulze, J.; Breckner, Amanda; Duncan, Polly; Scherer, Martin; Pohontsch, Nadine Janis; Lühmann, Dagmar

doi:10.1186/s12955-022-01993-z

Cited by 9 publications

(9 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high Kaiser-Meyer Olkin value (0.773) and the statistically significant Bartlett test of sphericity result ( p < 0.001) indicated sampling adequacy and were close to the values obtained in the previous validation studies [ 12 , 14 ]. The factor analysis of the question items suggested a three-factor solution, similar to two of the previous MTBQ validation studies [ 14 , 15 ]. The results showed that the Lithuanian version of MTBQ has high internal reliability, good construct validity and factor dimensionality.…”

Section: Discussionsupporting

confidence: 77%

Validation of the Lithuanian multimorbidity treatment burden questionnaire (MTBQ) and its association with primary care patient characteristics

Vasiliauskienė,

Vasiliauskas,

Duncan

et al. 2023

European Journal of General Practice

Self Cite

View full text Add to dashboard Cite

Background The increasing prevalence of multimorbidity among older people in Lithuania and other Central-Eastern European countries leads to a greater patient treatment burden and puts additional pressure on healthcare services. Objectives This study aimed to validate the Lithuanian version of the Multimorbidity Treatment Burden Questionnaire (MTBQ). Methods The Lithuanian version of the MTBQ was tested (2021-2022) with 789 patients from seven Lithuanian primary care centres who had two or more long-term conditions. The questionnaire translation’s reliability, validity and dimensionality of the were assessed with Spearman’s rank correlation, Cronbach’s alpha, and factor reduction analysis. Treatment burden and its associations with sociodemographic and other indicators were analysed. Results Lithuanian version of MTBQ had good internal reliability (Cronbach’s alpha 0.711), validity, factor reduction applicability, and interpretability. The MTBQ scores of the questionnaire had a negative association with the quality-of-life scale (r=-0.327, 95% CI [-0.389, −0.264]) and positive associations with the self-rated health scores ( r = 0.230, 95% CI [0.163, 0.297]) and with the number of comorbidities ( r = 0.164, 95% CI [0.097, 0.233]). Distribution of treatment burden was identified (none (19,4%), low (46,6%), medium (25%), high (9%)). High treatment burden was found to be associated with having five or more long-term diseases, taking five or more medications, having anxiety or depression and living in a rural area. Conclusion The study’s findings show that the MTBQ is applicable in assessing the treatment burden of multimorbid patients in Lithuania. Furthermore, the study demonstrates that Lithuanian patients with multimorbidity have average treatment burden scores similar to or higher than participants in previous MTBQ validation studies.

show abstract

Section: Discussionsupporting

confidence: 77%

Validation of the Lithuanian multimorbidity treatment burden questionnaire (MTBQ) and its association with primary care patient characteristics

Vasiliauskienė,

Vasiliauskas,

Duncan

et al. 2023

European Journal of General Practice

Self Cite

View full text Add to dashboard Cite

show abstract

“…A significant negative correlation was found between the global MTBQ and the EQ-5D-index, in line with previous findings. [ 22 , 30 ] Significant differences were also observed in the mean EQ-5D-index and EQ-VAS score among the treatment burden strata. Post-hoc analyses demonstrated significant differences among the treatment burden groups.…”

Section: Discussionmentioning

confidence: 98%

Treatment burden and health-related quality of life of patients with multimorbidity: a cross-sectional study

Gebreyohannes,

Gebresillassie,

Mulugeta

et al. 2023

Qual Life Res

View full text Add to dashboard Cite

Purpose The aim of this study was to investigate treatment burden and its relationship with health-related quality of life (HRQoL) among patients with multimorbidity (two or more chronic diseases) who were taking prescription medications and attending the outpatient department of the University of Gondar Comprehensive Specialized Teaching Hospital. Methods A cross-sectional study was conducted between March 2019 and July 2019. Treatment burden was measured using the Multimorbidity Treatment Burden Questionnaire (MTBQ), while HRQoL was captured using the Euroqol-5-dimensions-5-Levels (EQ-5D-5L). Results A total of 423 patients participated in the study. The mean global MTBQ, EQ-5D index, and EQ-VAS scores were 39.35 (± 22.16), 0.83 (± 0.20), and 67.32 (± 18.51), respectively. Significant differences were observed in the mean EQ-5D-Index (F [2, 81.88] 33.1) and EQ-VAS (visual analogue scale) scores (F [2, 75.48] = 72.87) among the treatment burden groups. Follow up post-hoc analyses demonstrated significant mean differences in EQ-VAS scores across the treatment burden groups and in EQ-5D index between the no/low treatment burden and high treatment burden, as well as between the medium treatment burden and high treatment burden. In the multivariate linear regression model, every one SD increase in the global MTBQ score (i.e., 22.16) was associated with a decline of 0.08 in the EQ-5D index (β − 0.38, 95%CI − 0.48, − 0.28), as well as a reduction of 9.4 in the EQ-VAS score (β − 0.51, 95%CI -0.60, − 0.42). Conclusion Treatment burden was inversely associated with HRQoL. Health care providers should be conscious in balancing treatment exposure with patients’ HRQoL.

show abstract

“…The Multimorbidity Treatment Burden Questionnaire(MTBQ) was originally developed and validated in United Kingdom (UK) [20], and has been translated into Danish [21], German [22] and French Canadian [23], demonstrating good content validity, construct validity and reliability. The Chinese Multimorbidity Treatment Burden Questionnaire (C-MTBQ) [10]was translated, culturally adapted and validated, to assess the treatment burden of multimorbidity in China.…”

Section: Measures Treatment Burdenmentioning

confidence: 99%

“…The global MTBQ score is calculated as the mean score, multiplied by 25, giving a score of 0 to 100. Global treatment burden scores can be categorized as: no (0), low (< 10), medium (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) and high treatment burden (≥22) [20].…”

Section: Measures Treatment Burdenmentioning

confidence: 99%

Treatment burden for older people with multimorbidity: a cross-sectional study in China

Dou

Jiang

Duncan

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background There has been little research in China about treatment burden. Studies internationally have found high treatment burden is associated with number of long-term conditions, low quality of life (QoL) iand poor medication adherence. The purpose of this study is to understand factors associated with high treatment burden for older people with multimorbidity in China. Methods A cross-sectional survey was conducted from February to May 2022. Through convenience sampling, 353 older people (≥ 60 years) with multimorbidity (≥ 2 long-term conditions) admitted to hospital in Zhengzhou, China, were invited to complete a survey including sociodemographic characteristics, long-term conditions and the Chinese version of Multimorbidity Treatment Burden Questionnaire (C-MTBQ). Ordinal logistic regression was used to identify the factors associated with high treatment burden. Results 342 older people with multimorbidity participated (response rate 92.2%) among whom, the prevalence of no, low, medium, and high treatment burden was 1.2% (4/342), 13.9% (44/342), 49.1% (168/342), and 36.8% (126/342), respectively. Ordinal logistic regression analysis found high treatment burden was associated with age, monthly household income, type of medical insurance, and number of long-term conditions. Conclusion Most surveyed older people with multimorbidity experienced medium-to-high treatment burden. Policy makers and service providers should focus particularly on people at risk of higher treatment burden, namely older people with low income, New Rural Cooperative and high number of long-term conditions. Policy should be addressed to reduce health inequalities from different types of medical insurance.

show abstract

Adaptation and validation of a German version of the Multimorbidity Treatment Burden Questionnaire

Cited by 9 publications

References 45 publications

Validation of the Lithuanian multimorbidity treatment burden questionnaire (MTBQ) and its association with primary care patient characteristics

Validation of the Lithuanian multimorbidity treatment burden questionnaire (MTBQ) and its association with primary care patient characteristics

Treatment burden and health-related quality of life of patients with multimorbidity: a cross-sectional study

Treatment burden for older people with multimorbidity: a cross-sectional study in China

Contact Info

Product

Resources

About